Picture loading failed.

Anti-TNFRSF4 therapeutic antibody (Pre-made Cudarolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cudarolimab (formerly IBI 101) is a recombinant fully human anti-OX40 (tumour necrosis factor receptor superfamily member 4) monoclonal antibody, being developed by Innovent Biologics, for the treatment of various cancers, including solid tumours, and hepatitis B.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-126-1mg 1mg 3090
GMP-Bios-ab-126-10mg 10mg 21890
GMP-Bios-ab-126-100mg 100mg 148000
GMP-Bios-ab-126-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF4 therapeutic antibody (Pre-made Cudarolimab biosimilar,Whole mAb)
INN Name Cudarolimab
TargetTNFRSF4
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesInnovent Biologics
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna